JAK1 and acute lymphoblastic leukemia: We observed that treatment of pre‐B ALL cells lacking active XBP1 with BEZ235 resulted in aberrant expression of NRASG12D and its downstream target Dusp6 while phosphorylation levels of STAT5 and JAK1 strongly decreased.